Johnson & Johnson (NYSE: JNJ) has launched the Shockwave C2 Aero Fly Coronary Intravascular Lithotripsy (IVL) Catheter in the United States, a device designed to treat calcified coronary artery lesions in less time than previous IVL devices, according to a company press release.

The catheter delivers pulses at 2 Hz, reducing total treatment time to 115 seconds compared with 230 seconds for prior-generation devices. Pause time between pulsing cycles is also reduced to five seconds, a 50% decrease from earlier models. The company states the shorter balloon inflation time lowers the duration of temporary blood flow blockage during the procedure.

The device builds on the Shockwave C2 Aero platform, which Johnson & Johnson acquired through its purchase of Shockwave Medical. Safety and effectiveness data for the 2 Hz system were published in the journal JACC Cardiovascular Interventions in March 2026, based on the Disrupt CAD Duo IDE Study.

"In the cath lab, every second matters, especially as we see more complex cases and higher procedure volumes," said Hector Tamez Aguilar, M.D., interventional cardiologist at Piedmont Healthcare in Atlanta, Georgia, who is a paid consultant for Shockwave Medical. "Shockwave C2 Aero Fly enables faster workflows, helping physicians treat calcified coronary disease more efficiently."

Coronary artery disease affects an estimated 315 million people worldwide and approximately 1 in 20 adults over age 20 in the U.S., according to the Centers for Disease Control and Prevention.

The Shockwave C2 Aero Fly is now available in the U.S. Johnson & Johnson plans to feature the device at the TCT 2026 conference in San Diego, California, from October 31 to November 3, 2026.